Agents against common colds, SARS and other coronaviral diseases
Human coronaviruses (HcoV) are the major cause of diseases of the upper respiratory tract in humans. Apart from the common cold these include e.g. the life-threatening severe acute respiratory syndrome (SARS), that, originating in China, has appeared in other parts of the world with a mortality rate of 15%. A key enzyme for the replication cycle of the coronavirus is the HcoV proteinase Mpro. The functional relevance of Mpro makes it an attractive target for the development of drugs against SARS and other coronaviral diseases.
The present invention relates to a group of anticoronaviral agents whose functional mechanism is based on the specific blockade of the substrate binding site of HCoV Mpro. In vitro test systems have shown the substances according to the invention to be highly effective against several coronaviruses.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
“Nanostitches” enable lighter and tougher composite materials
In research that may lead to next-generation airplanes and spacecraft, MIT engineers used carbon nanotubes to prevent cracking in multilayered composites. To save on fuel and reduce aircraft emissions, engineers…
Trash to treasure
Researchers turn metal waste into catalyst for hydrogen. Scientists have found a way to transform metal waste into a highly efficient catalyst to make hydrogen from water, a discovery that…
Real-time detection of infectious disease viruses
… by searching for molecular fingerprinting. A research team consisting of Professor Kyoung-Duck Park and Taeyoung Moon and Huitae Joo, PhD candidates, from the Department of Physics at Pohang University…